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ORIGINAL ARTICLE
Metabolic proﬁling of polycystic ovary syndrome reveals
interactions with abdominal obesity
A Couto Alves1,14, B Valcarcel2,14, V-P Mäkinen3,4,5, L Morin-Papunen6, S Sebert7,8, AJ Kangas5, P Soininen4,9, S Das1, M De Iorio10,
L Coin1, M Ala-Korpela4,8,9,11, M-R Järvelin1,7,8,12,14 and S Franks13,14
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common reproductive disorder associated with metabolic disturbances
including obesity, insulin resistance and diabetes mellitus. Here we investigate whether changes in the metabolic proﬁle of PCOS
women are driven by increased tendency to obesity or are speciﬁc features of PCOS related to increased testosterone levels.
DESIGN AND METHODS: We conducted an NMR metabolomics association study of PCOS cases (n= 145) and controls (n= 687)
nested in a population-based birth cohort (n= 3127). Subjects were 31 years old at examination. The main analyses were adjusted
for waist circumference (WC) as a proxy measure of central obesity. Subsequently, metabolite concentrations were compared
between cases and controls within pre-deﬁned WC strata. In each stratum, additional metabolomics association analyses with
testosterone levels were conducted separately among cases and controls.
RESULTS: Overall, women with PCOS showed more adverse metabolite proﬁles than the controls. Four lipid fractions in different
subclasses of very low density lipoprotein (VLDL) were associated with PCOS, after adjusting for WC and correction for multiple
testing (Po0.002). In stratiﬁed analysis the PCOS women within large WC strata (⩾ 98 cm) had signiﬁcantly lower high density
lipoprotein (HDL) levels, Apo A1 and albumin values compared with the controls. Testosterone levels were signiﬁcantly associated
with VLDL and serum lipids in PCOS cases with large WC but not in the controls. The higher testosterone levels, adjusted for WC,
associated adversely with insulin levels and HOMA IR in cases but not in the controls.
CONCLUSIONS: Our ﬁndings show that both abdominal obesity and hyperandrogenism contribute to the dyslipidaemia and other
metabolic traits of PCOS which all may negatively contribute to the long-term health of women with PCOS.
International Journal of Obesity (2017) 41, 1331–1340; doi:10.1038/ijo.2017.126
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common endocrinopathy in
women that affects both reproductive and metabolic function.1
PCOS is characterised by metabolic disturbances, particularly
insulin resistance and other features of metabolic syndrome that
translate into an increased risk of developing type 2 diabetes and
cardiovascular disease.
We have previously shown that women with symptoms of PCOS
in an unselected general population of northern Finland2 have
endocrine and metabolic indices which are characteristic of
patient populations with clinically diagnosed PCOS and suggest
increased cardiovascular disease risk.3,4 However, women with
PCOS who have either hyperandrogenism without cycle dis-
turbances or anovulation but with normal androgens levels, are
less likely to have metabolic abnormalities.5 Although there is
evidence that women with PCOS have increased tendency to
obesity and abnormalities of lipids and lipoproteins,4,6 there is still
controversy5,7 about whether the adverse metabolic indices are
mainly related to the syndrome itself or whether they are simply a
reﬂection of obesity and/or abdominal fat distribution.
Comprehensive approaches to gain insights into metabolic
variation and diseases, by more reﬁned metabolic phenotyping,
have become increasingly popular.8–13 Recent metabolic proﬁling
studies have discovered novel molecular markers associated with
the risk for diabetes14,15 and cardiovascular disease.16–18 Metabo-
lomics is increasingly applied to study complex diseases and the
relatively new serum nuclear magnetic resonance (NMR) metabo-
lomics platform provides a powerful tool for high-throughput
quantitative metabolic proﬁling.19–21
Here, we present the application of quantitative serum
metabolomics to study an extensive sample of a population-
based cohort of women with PCOS, and an age-matched
reference population. We investigated the metabolic proﬁle of
PCOS to determine the impact of abdominal obesity, a feature
associated with adverse metabolic function and a common
ﬁnding in women with PCOS, on metabolic and endocrine health.
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Because hyperandrogenism may contribute to adipocyte dysfunc-
tion and dyslipidemia in PCOS we also assessed whether the
adverse changes in the metabolic proﬁle were associated with
testosterone levels. Finally, we analysed whether testosterone
levels were associated with fasting insulin and insulin resistance,
as measured by the homoeostatic model assessment (HOMA IR).
The combination of a large, carefully designed population sample,
state-of-the art metabolic proﬁling and extensive laboratory and
phenotypic database enabled us speciﬁcally to interrogate the
complex relationships between PCOS and its metabolic co-
morbidities. We were therefore able to relate metabolic indices
not only to abdominal obesity but also, independently, to the
degree of androgen excess.
MATERIALS AND METHODS
Study population
The whole general population-based study comprises 3127 women of the
Northern Finland Birth Cohort 1966 who were studied at the age of 31
years. Blood samples were drawn after overnight fasting and serum
samples were stored at − 80 °C until testosterone and metabolite
concentration analyses (methods described previously22). Samples were
not speciﬁcally timed to any phase in the menstrual cycle. We excluded
pregnant women, subjects with type 1 or type 2 diabetes, those on oral
contraceptives, insulin-sensitising drugs, and on lipid lowering and anti-
hypertensive treatments. From all eligible women for the present study
12% were excluded while on contraceptives, further 4% due to other
above reasons. All subjects provided written informed consent. The Ethical
Committee of the Northern Ostrobothnia Hospital District (Finland)
approved the study.
Clinical and biochemical evaluation of the study population
From among the whole population the women with symptoms of PCOS
who met the NICHD (National Institute for Health) diagnostic criteria for
PCOS were included in the case group.23 Overall, after above exclusions,
145 women were diagnosed with PCOS according to the following criteria:
the presence of oligo- or amenorrhoea and hyperandrogenism (clinical,
that is, hirsutism and/or biochemical). The reference, control, group (687
women) did not present any of these features and was age-matched by
birth cohort design. Biochemical hyperandrogenism was deﬁned as serum
testosterone concentration 42.4 nmol l− 1. The cut-off value was derived
as previously described3,24 and corresponds to the 75% quartile of the
distribution of testosterone values in the reference population.4 We
deﬁned three strata of waist circumference (WC⩽ 87 cm, 87oWCo98
and WC⩾ 98), which were chosen according to well-established criteria
derived from a large prospective population study on all-cause mortality.25
Metabolite quantiﬁcation
The metabolic data were acquired using a high-throughput serum NMR
metabolomics platform. The quantiﬁed metabolites include 138 measures
related to lipoprotein subclasses, serum proteins, lipids, fatty acids and
abundant low molecular-weight metabolites, including glycolysis sub-
strates, amino acids, ketone bodies and other small molecules, as listed in
Supplementary Table 1. Details of the experimental protocols including
sample preparation and spectroscopy have been described previously.19–21
Statistical analysis
We conducted an overall metabolomics association analysis using logistic
regression with PCOS as outcome, with and without (not shown) adjusting
for WC as a good proxy for central obesity (in these analyses metabolite
measurements were standardised to unit variance). We then stratiﬁed the
data set based on WC. In each WC stratum, we applied a Welch t-test to
estimate the metabolite concentration differences between cases and
controls complemented with a two-way ANOVA for detecting interactions
across strata. In addition, we conducted a linear regression analysis
separately in cases and controls, adjusting for WC in each strata to assess
differences in the metabolite associations with testosterone. The model ﬁt
to each WC strata in cases and controls separately was: testosterone=
metabolite+WC. We stratify and correct for WC to avoid residual
confounding. A Student’s t-test was applied to the normally distributed
test-statistic (βpcos− βcontrol)/sqrt(s.e.pcos2 +s.e.control2 ) to assess the statistical
signiﬁcance of the regression coefﬁcient difference between cases and
controls. We corrected for multiple hypothesis testing with the Bonferroni
method by adjusting for the number of independent tests estimated with
the Li and Ji method26 based on principal component analysis (PCA).27 The
P-value o0.002 was considered as statistically signiﬁcant. We report the
relative difference in the regression coefﬁcient or the relative difference in
the mean concentration level as (X− Xreference)/Xreference. We assessed the
impact of potential confounding by smoking, alcohol consumption and
social-economic status which showed that495% of the PCOS associations
with lipoproteins, low molecular weight metabolites and lipids were not
Table 1. Clinical and biochemical characteristics of women with PCOS by the NICHD criteriaa and their controls
Cases, n= 145 Controls, n=687 P-value
95% CI 95% CI
Mean Lower Upper s.d. Mean Lower Upper s.d.
Waist circumference (cm) 84.9 82.3 87.5 16.5 78 77.2 78.9 11.2 7.4E− 6
Waist-hip ratio 0.84 0.83 0.85 0.08 0.8 0.79 0.81 0.1 9.2E− 6
BMI (kg m−2) 26.5 25.5 27.6 6.6 23.7 23.4 24.1 4.4 9.1E− 6
HOMA insulin resistance (IR) 1.25 1.13 1.37 0.73 0.98 0.95 1.01 0.41 3.5E− 5
HOMA beta cell function 108.7 103 114.4 35.6 97.5 95.7 99.3 24.6 5.5E− 4
HOMA insulin sensitivity 98.5 92.2 104.9 39.8 114.7 112 117.4 36.7 2.3E− 5
Glucose (mmol l− 1) 5.0 4.9 5.1 0.4 4.9 4.86 4.94 0.5 1.8E− 2
Insulin (mU l− 1) 9.7 8.8 10.6 5.8 7.6 7.4 7.8 3.2 3.7E− 5
SHBG (nmol l− 1) 56.5 49.7 63.3 42 65.9 63.4 68.4 33.5 1.5E− 2
Testosterone (nmol l− 1) 2.9 2.7 3.0 1.0 1.6 1.57 1.63 0.4 1.2E− 34
Luteinizing hormone (U l− 1) 10.8 7.7 13.8 18.8 6.1 5.6 6.6 6.9 4.9E− 3
Systolic blood pressure (mmHg) 122.0 119.2 124.5 13.8 118.6 117.7 119.5 11.7 6.0E− 3
Diastolic blood pressure (mmHg) 77.1 75.6 79.5 11.7 74 73.2 74.8 10.3 1.0E− 3
Total cholesterol (mmol l− 1) 5.0 4.8 5.2 1.0 4.8 4.7 4.9 0.9 1.1E− 2
LDL cholesterol (mmol l− 1) 3.0 2.8 3.1 0.9 2.75 2.7 2.8 0.9 1.2E− 2
HDL cholesterol (mmol l− 1) 1.5 1.5 1.6 0.4 1.7 1.67 1.73 0.4 8.9E− 4
Triglycerides (mmol l− 1) 1.1 1.0 1.2 0.6 0.86 0.83 0.89 0.4 8.1E− 6
Abbreviations: HDL, high density lipoprotein; HOMA, homoeostatic model assessment; LDL, low density lipoprotein; SHBG, sex hormone binding globulin. aBy
National Institute for Health, USA.
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signiﬁcantly affected (o10% of their original regression coefﬁcient) by
adding smoking, alcohol or socio-economic status as covariates
(Supplementary Table 2). Consequently, we used a reduced model
adjusting for or statifying by WC in this study. All analyses were conducted
with the R statistical package.28
RESULTS
Clinical characteristics
In total, 145 women with PCOS by the NICHD diagnostic criteria
and their 687 controls were included in the metabolomic analysis.
By deﬁnition, all cases had oligo- or amenorrheoa and clinical and/
or biochemical evidence of androgen excess. 104 cases (77%) had
raised serum testosterone, including all those women who did not
report being affected by hirsutism. Of those who complained of
hirsutism, 53% also had raised serum testosterone. Table 1 shows
a comparison of the clinical and biochemical characteristics of
women with and without PCOS depicting typical metabolic and
endocrine characteristics such as dyslipidaemia, increased insulin
resistance, poorer beta cell function, higher diastolic and systolic
blood pressure (SBP, DBP), higher luteinizing hormone (LH) and
lower sex hormone binding globulin (SHBG) in women with PCOS.
Overall metabolomics association analyses
In order to further characterise the metabolic proﬁle of PCOS
women compared with the controls, we conducted an association
analysis of lipoprotein subclasses, lipids and low molecular weight
metabolites. Figure 1 shows the metabolome-wide pattern of
these associations adjusted for WC in order to report the estimates
independent of central obesity. Women with PCOS showed
several differences from the reference population in the metabolic
proﬁle of the VLDL subclasses. Four lipid measures in four different
subclasses of VLDL were associated with PCOS at Po0.002 (PCA-
based Bonferroni-corrected P-value; Figure 1). In addition, seven
lipid measures in three different VLDL subclasses showed a
suggestive association (Po0.004).
Supplementary Tables 3–5 show detailed association analyses
of lipoproteins, lipids and low molecular weight metabolites with
PCOS. Overall, triglyceride metabolism was associated with PCOS
mainly via larger VLDL particles and total triglycerides levels.
Supplementary Table 3 shows that particularly, the total amount
of lipids in extremely large VLDL (XXL subclass in Figure 1), the
levels of triglycerides in medium VLDL subclasses, cholesterol
esters in large VLDL and triglycerides in small VLDL were positively
associated with PCOS (odds ratio, OR42.08 by SD unit increase in
metabolite level, Po2 × 10− 3). The total amount of lipids, total
cholesterol and the total concentration of cholesterol in medium
and large VLDL particles, as well as the phospholipids and free
cholesterol in medium VLDL and the triglycerides in large and very
large VLDL were suggestively (Po0.004) associated with
increased risk of PCOS (Supplementary Table 3). However, none
of the fatty acids, amino acids or low molecular weight
metabolites in serum showed statistically signiﬁcant association
with PCOS in these overall central obesity-adjusted analyses
(Supplementary Tables 4 and 5). Analyses were repeated after
adjusting for alcohol consumption, smoking and socio-economic
status but results did not change substantially. A subset of data,
illustrating and comparing metabolite proﬁles of PCOS women
and controls by different strata of WC, is shown in Figure 2. Here,
all 4 signiﬁcant metabolites were associated with PCOS, idepen-
dently of WC, in the logistic regression analysis.
Analysis of metabolites stratiﬁed by waist circumference
To further understand the interaction between body fat distribu-
tion and biochemical data in PCOS women, we conducted a
stratiﬁed analysis of metabolites by the pre-ordained tertiles of WC
in both cases and controls. We found 18 metabolites signiﬁcantly
associated with PCOS in women with large waist circumference
(WC498 cm), only one in the middle WC stratum, but none in
women with smaller WC (Supplementary Tables 6 and 7).
Interestingly, the metabolic ‘impact’ of PCOS was modest in
women with a small waist circumference apart from a tendency
for higher (Po0.05) VLDL cholesterol and triglycerides
(WC⩽ 87 cm) (Figure 3). In the intermediate stratum
(87 cmoWCo98 cm) only the ratio of omega 6/7 to total fatty
acids was statistically signiﬁcantly lower in PCOS women than
their controls (Supplementary Table 6). In the large waist
circumference stratum, the concentration of phospholipids,
cholesterol, free cholesterol and cholesterol esters in HDL
subclasses were signiﬁcantly (Po0.002) decreased, as well as
the diameter and concentration of HDL particles. Albumin
concentration and total choline were lower in PCOS women
compared with the controls (Supplementary Tables 6 and 7). In
the large WC stratum (Figure 3), the concentration of the
cholesterol in LDL, fatty acids and gluconeogenic metabolites
showed a decreasing tendency (Po0.05) in women with PCOS
while the ratio of Apo B/Apo A1 showed an increasing tendency
(Figure 3). Interestingly, the impact of WC on HDL proﬁle was
stronger in women with PCOS than controls, that is, PCOS women
had lower HDL values. In particular, the average magnitude of
change in HDL lipid proﬁle between small and large WC in PCOS
women was 32% as opposed to only 12% in controls
(change= 100%× |ClargeWC− ClowWC|/ClowWC). In the intermediate
level of WC, the change was smaller (13 and 7%) but the relative
difference between cases and controls was still considerable.
There were no statistically signiﬁcant differences in low molecular
weight metabolites between cases and controls by WC strata (data
not shown). In conclusion, women with PCOS and abdominal
obesity (waist circumference⩾ 98 cm) had an altered metabolic
proﬁle in terms of HDL subclasses, total choline, albumin,
apolipoprotein A1 and Apo B/Apo A1 ratio.
Relationship of metabolic proﬁles to serum testosterone
We examined (a) whether the differences in concentration levels
of HDL, apolipoproteins and other metabolites were related to
higher testosterone levels in women with PCOS compared with
the controls and (b) how this relationship was affected by central
obesity. We therefore conducted a metabolite association analysis
with testosterone separately in women with PCOS and controls for
all WC strata (also adjusting for WC in strata).
We found 8 signiﬁcant associations of testosterone with lipids
and 22 with lipoproteins in PCOS women with large (WC⩾ 98) but
not in women with intermediate and smaller waist circumference
(except for one positive association with the ratio of omega 6 and
7 in intermediate strata). The relationship of testosterone with
VLDL, and to a lesser extent LDL and HDL proﬁles, showed
signiﬁcant differences between the cases and controls (Figure 4).
The associations for strata of WC⩾ 98 are shown in Supplementary
Tables 8–10.
The lipid proﬁle of PCOS women with abdominal obesity was
highly associated with testosterone (Figure 4; Supplementary
Table 8). Total triglycerides, the ratio of triglycerides to
phosphoglycerides, omega-9 and saturated fatty acids, the ratio
of omega-9 and saturated fatty acids to total fatty acids and the
average number of methylene groups per double bond showed
positive association with levels of testosterone in PCOS women
but not in controls (β40.17, Po1.9 × 10 − 3). Conversely, the ratio
of bisallylic groups to fatty acids, the ratio of bisallylic groups to
double bonds as well as the average number of double bonds in
fatty acid chains were all negatively associated with levels of
testosterone in PCOS women but not in controls (βo − 4.9,
Po1.6 × 10 − 3).
The lipoprotein proﬁle of PCOS women with abdominal obesity
showed positive group-speciﬁc associations with testosterone
NMR MWAS on PCOS
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Figure 1. Metabolome-wide pattern of associations with PCOS compared with controls adjusted for waist circumference (− log10 P-values).
Four metabolites in four different VLDL subclasses are signiﬁcantly associated with PCOS (Bonferroni-corrected signiﬁcance level α= 0.002)
independently of WC. Multiple metabolites characterising the larger VLDL and intermediate HDL subclasses showed a tendency (Po0.05) for
association with PCOS. The red bars denote the − log10 P-value of each metabolite, a longer bar indicates a lower P-value and therefore higher
signiﬁcance.
Figure 2. Metabolite proﬁles in PCOS and control women stratiﬁed by WC, illustrating the four metabolites that showed the most signiﬁcant
(Po0.002) associations with PCOS that are independent of WC, as identiﬁed using logistic regression analysis.
NMR MWAS on PCOS
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levels (Supplementary Table 9). In the set of statistically signiﬁcant
associations with testosterone, the difference in regression
coefﬁcient between cases and controls remained statistically
signiﬁcant after correction for multiple comparisons for most
metabolites. Triglycerides in the larger VLDL subclasses, the serum
concentration of VLDL particles, the VLDL mean diameter as well
as the phospholipids and total lipids in VLDL subclasses (ranging
from medium to extremely large particles), and the total
cholesterol, cholesterol esters and free cholesterol in large VLDL
subclasses were all positively associated with testosterone levels
(β40.73, Po1.4 × 10− 3). Conversely, the mean diameter of LDL
particles showed a negative association with testosterone levels in
PCOS women but not in controls (β=− 3.4, P= 3.9 × 10− 4). We did
not ﬁnd signiﬁcant associations of testosterone with low
molecular weight metabolites in overall analyses or by WC strata
(Supplementary Table 10).
Figure 3. Mean serum metabolite difference between PCOS cases and controls by three waist circumference (WC) strata (⩽87, 87oWCo98,
WC⩾ 98 cm). Overall there are 18 metabolites signiﬁcantly associated with PCOS in women with large waist circumference (only 8 of which are
plotted here, see Supplementary Tables 6–7 for full results), while there were no signiﬁcant differences in lean women. The points and lines
indicate the mean differences with their 95% conﬁdence intervals between cases and controls in standard deviations. The relative difference
was calculated from the original data without scaling as [mean(cases)−mean(controls)]/mean(controls). Signiﬁcant and suggestive differences
after multiple testing correction indicated with speciﬁc characters. Serum metabolites levels that are higher in PCOS cases are in red and those
that are lower in blue. Omega 3 FA ratio, omega 6,7 FA ratio and omega-9 FA ratio denote the omega metabolite ratio to total fatty acids. Apo
denotes apolipoprotein; FA, fatty acid; HDL, high density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein;
TG, triglycerides; VLDL, very low density lipoprotein.
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Testosterone relationship to insulin resistance
In order to investigate further the role on testosterone on the
glycaemic status in PCOS we conducted a regression analysis of
fasting insulin levels and an index of insulin resistance (HOMA IR)
(Table 2) adjusting for WC.
Testosterone levels were associated with insulin levels in cases
(β= 0.71, P= 0.047) but not in controls (β= 0.003, P= 0.99). There
was a suggestion that the impact of testosterone on insulin levels
was stronger (P= 0.096) in PCOS, indicating possible differences in
the relationship between insulin and testosterone between PCOS
and the reference group.
Testosterone was also signiﬁcantly associated with insulin
resistance (HOMA IR) in cases (β= 0.092, P= 0.042) but not in
controls (β= 0.001, P= 0.97). Interestingly, the association of WC
Figure 4. Serum metabolite associations with testosterone levels in PCOS cases and controls with large waist circumference (WC⩾ 98). Overall
there are 30 metabolites signiﬁcantly associated with testosterone in PCOS but not in control women with large waist circumference (only 6 of
these plotted here, see Supplementary Tables 8–10 for full data set), suggesting that androgens levels correlate with adverse metabolic
proﬁles of VLDL and lipid fractions in abdominally obese but not in otherwise lean PCOS women. No associations found in lean or
intermediate obese women. The points and horizontal lines indicate the regression coefﬁcient slopes (β) for testosterone with their 95%
conﬁdence intervals in cases and controls. Betas presented in standard deviation (s.d.) units and the beta difference was calculated as
β(cases)− β(controls) and presented in s.d. units. Signiﬁcant and suggestive differences, after correction for multiple testing, indicated with
speciﬁc characters. Serum metabolites levels that are positively associated with testosterone are in red and those that are negatively
associated in blue. Omega 3 FA ratio, omega 6,7 FA ratio and omega-9 FA ratio denote the omega metabolite ratio to total fatty acids. Apo
denotes apolipoprotein; FA, fatty acid; HDL, high density lipoprotein; IDL, intermediate density lipoprotein; LDL, low density lipoprotein;
TG, triglycerides; VLDL, very low density lipoprotein.
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with insulin levels or resistance was signiﬁcantly stronger in cases
(Po3.7 × 10− 5) than in the controls.
DISCUSSION
Metabolic abnormalities are a common feature of women with
PCOS but there remains controversy about whether such
abnormalities, in particular dyslipidemia, are a function of
PCOS itself or of accompanying obesity, and, in particular
abdominal obesity which is a well-established risk factor for
metabolic and cardiovascular disease. We reasoned that since
PCOS itself is associated with increased risk factors for
cardiovascular disease, the impact of PCOS diagnosis, over
and above the effect of obesity, would compound that risk. This
study sought to address this question by a comprehensive
characterisation of the metabolic proﬁle of PCOS women using,
for the ﬁrst time in this context, the serum concentrations of
metabolites analysed by state of the art quantitative NMR
metabolomics platform in a large cohort of women who met
the NICHD diagnostic criteria for PCOS. We conducted both WC
stratiﬁed and adjusted analyses and assessed the impact of
testosterone levels on the metabolic proﬁle of PCOS and control
women over a range of WC. We found a signiﬁcant interaction
between obesity, testosterone and dyslipidemia in women with
PCOS, which indicates that the syndrome itself is an important
player in the lipoprotein abnormalities beyond the effects of
obesity per se.
Association analysis
Previous studies have shown that dyslipidemia is common in
PCOS.29,30 In particular, triglycerides and LDL cholesterol have
been found to be higher in women with PCOS, while HDL-C was
lower. Metabolomic studies have previously been performed in
women with PCOS31–34 but with the exception of that by Zhao
et al. (2012), the numbers of PCOS subjects involved have been
small and no other study has included a large, matched reference
population or stratiﬁed the results systematically to account for
the effects of abdominal obesity and serum testosterone.
In our study, adjusting for WC and using a state of the art
metabolomics platform, the lipoprotein proﬁle showed indepen-
dent associations of various VLDL subclasses with PCOS. After
correction for multi-comparison, triglycerides in small and
medium VLDL subclasses were positively associated with PCOS,
which is consistent with the literature that shows an overall
increase of TG levels in VLDL.35 We also found that cholesterol
esters in large VLDL and the total amount of lipids in extremely
large VLDL (which are new markers that were measured using the
metabolomics platform) were increased in PCOS. Lipid content in
VLDL subclasses, which has previously been shown to be
associated with obesity, was investigated in this study using a
stratiﬁed analysis. Interestingly, although we analysed 14 lipopro-
tein subclasses characterising all major fractions (VLDL, IDL, LDL
and HDL), only lipid measures in larger VLDL subclasses were
affected in women with PCOS.
Stratiﬁed analysis
Previous studies36,37 have found that both lean and obese women
show signs of insulin resistance and reduced levels of cholesterol
in HDL, HDL2 and HDL3 subclasses. PCOS women, as opposed to
controls, have shown signiﬁcantly decreased insulin sensitivity
with increasing BMI36 and low-grade chronic inﬂammation.38
In the present study, using a stratiﬁed analysis by WC, we found
decreased HDL cholesterol in PCOS women with abdominal
obesity, which is consistent with results of previous studies4,39–41
in which stratiﬁcation by BMI was used. We also found new
biochemical markers of PCOS in women with abdominal obesity,
including albumin and total choline. In a recent study albumin
levels have been associated with increased total mortality.42
Importantly, our results show that the lipid proﬁle of HDL
subclasses is signiﬁcantly more inﬂuenced by the degree of
abdominal obesity in PCOS women than in controls. Phospholi-
pids, total cholesterol, free cholesterol, cholesterol esters and total
lipids in the larger HDL subclasses were lower in PCOS. Consistent
with these results, the concentration and the mean diameter of
HDL particles were smaller in PCOS women with abdominal
obesity. These changes in HDL concentration and HDL particle size
are known to be associated with coronary artery disease43 and
may increase susceptibility to coronary events.44
Importantly, Apo A1 concentrations in PCOS women with
abdominal obesity were signiﬁcantly lower than in controls, which
is also shown to be accompanied by lower HDL levels. Previous
studies39 in obese and overweight women (BMI427) did not ﬁnd
a signiﬁcant difference, possibly due to smaller sample size or due
to stratiﬁcation by BMI instead of WC. Our association analysis
results were consistent with this ﬁnding, showing that the ratio of
Apo B and A1 was positively associated with PCOS. The
multivariate pattern of decreased Apo A1, HDL-C and HDL-
phospholipids have been previously linked to inﬂammation-
associated dyslipidaemia in obesity.45 This is corroborated by
previous cross-sectional studies that found elevated CRP levels
and increased low-grade chronic inﬂammation in PCOS women.46
These results suggest that PCOS women may indeed be at higher
risk of cardiovascular diseases such as atherosclerosis. To date, we
lack secure longitudinal data on cardiovascular events in women
with PCOS but the data here support the view that PCOS women
who carry these risk factors may require careful clinical monitoring
from an early age.47
Relationship of metabolites to serum testosterone levels
Previous interventional studies showed that intramuscular injec-
tions of testosterone esters in young females undergoing gender
reassignment increased visceral fat48 and resulted in insulin
resistance49 and so did the administration of oral
Table 2. The relationship of fasting insulin and insulin resistance (HOMA IR) with testosterone levels
Outcome Exposure Cases Controls Beta difference
β s.e. P-value β s.e. P-value P-value
Insulin (mU l− 1) Testosterone (nmol l− 1) 0.712 0.354 4.70E− 02 0.003 0.236 9.90E− 01 9.6E− 02·
(Model 1) WC (cm) 0.242 0.021 2.00E− 16 0.147 0.009 2.00E− 16 2.80E− 05
HOMA IR Testosterone (nmol l− 1) 0.092 0.045 4.20E− 02 0.001 0.031 9.70E− 01 9.5E− 02·
(Model 2) WC (cm) 0.031 0.003 2.00E− 16 0.019 0.001 2.00E− 16 3.70E− 05
Abbreviation: HOMA, homoeostatic model assessment. Model 1: Insulin= Testosterone+WC; Model 2: HOMA IR= Testosterone+WC; Beta values for insulin and
HOMA IR levels are mutually adjusteda and by unit increase in exposure level. aThe association between testosterone and outcomes are adjusted for waist
circumference (WC) and between WC and outcome by testosterone.
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methyltestosterone to healthy pre-menopausal women.50 Mirror-
ing these observations in adolescent girls with PCOS, metabolic
syndrome risk increased 4-fold for every quartile increase in
testosterone after adjusting for SHBG.51 The application of
subcutaneous testosterone implants in women with pre-
menstrual syndrome decreased Apo A1 and HDL-C and increased
VLDL-C, while in pre-menopausal obese women, the same
treatment showed a small decrease of serum HDL-C and TC.52 In
contrast, in PCOS women, the free androgen index (Testosterone/
SHBG) was positively correlated with TC, TG, LDL-C, Apo B and
phospholipids (PL) (although after adjusting for age and BMI the
association was not signiﬁcant).
In our study, PCOS women with abdominal obesity showed
differences in the lipid and lipoprotein proﬁles in relation to serum
testosterone. In these women, testosterone levels were positively
associated with serum TG as well as with PL, TG and TC in larger
VLDL subclasses, which is consistent with other reported studies in
women with PCOS. However, we did not ﬁnd the negative
associations of testosterone with Apo A1 and HDL-C that have
been observed in interventional studies of testosterone treatment.
This suggests that the impact of testosterone on lipid metabolism
in PCOS differs from control women with normal pre-treatment
androgen levels. We also found that total lipids in VLDL subclasses
were positively correlated with testosterone, the concentrations
and mean diameters of larger VLDL particles were also positively
correlated with testosterone, while the mean diameter of LDL
particles was negatively correlated. Interestingly, omega-9 and
saturated fatty acids were also positively correlated with
testosterone. These novel markers may have public health
signiﬁcance as larger VLDL particle size is associated with type 1
diabetes in women53 and PCOS women are recommended a diet
with increased levels of omega-9 (a monounsaturated fatty
acid—MUFA).54 The rise of VLDL and decrease of HDL associated
with high testosterone levels potentially increase cardiovascular
disease risk. These metabolic characteristics are exacerbated in
women with PCOS and abdominal obesity (WC⩾ 0.98) suggesting
an interaction between testosterone and abdominal obesity that
putatively affect metabolic risk factors of cardiovascular disease.
The converse is that this relationship is not observed in women
with PCOS who have normal WC which is important in counselling
women witth PCOS about metabolic risk. Taken together, these
results suggest that high testosterone levels adversely affect a
range of metabolites, modulate the risk for metabolic syndrome,
diabetes and cardiovascular disease and have an important role in
the pathophysiology of PCOS. Our results are consistent with the
conclusions of the recent study by Dumesic and colleagues that
hyperandrogenism, even in lean women with PCOS, is associated
with preferential deposition of intraabdominal fat that in turn
results in impaired storage of fat in subcutaneous adipocytes and
consequent metabolic dysfunction.55 It is conceivable that the
dyslipidemia that we observe in women with PCOS is explained, at
least in part, by the impact of excess androgens on the ability of
adipocytes to safely store excess fat.
Strengths and limitations
A major strengths of the study are the systematic stratiﬁcation and
adjustment of analyses for WC as a measure of abdominal obesity
and the homogeneity of the study populaton. Both cases and their
controls were retrived from the NFBC1966, extremely well
characterised general population sample. This eliminates, as far
as possible, the bias often encountered in these studies. Blood
samples were not taken at the same stage of the cycle in women
with regular menses. This might conceivably introduce some bias
in interpretation of lipid levels but the available data are
inconsistent and any such cyclical variation is small and most
obvious in the preovulatory phase.56 But effectively the sampling
was randomly performed, thus minimising any possible effect of
cyclical changes. Although cases with PCOS were initially selected
on the basis of self-reported symptoms, we only included subjects
in the study group who met the criteria for the NIHCD deﬁnition of
the syndrome. All PCOS women included here suffered from
infrequent or absent periods and had clinical and/or biochemical
evidence of hyperandrogenism. Signiﬁcantly, 77% of women
complaining of hirsutism had a raised serum testosterone level.
Furthermore, we have shown, in previous studies, that the
biochemical characteristics of those women with self-reported
symptoms of PCOS are very similar to clinic-based patients with
PCOS.2 That is particularly the case in those women in the cohort
who have both oligomenorrhea and hyperandrogenism. We
recognise that HOMA IR is not an ideal index of insulin resistance
but in general population studies it is often impractical to perform
euglycemic hyperinsulinemic clamp studies in all subjects and, in
this case, HOMA IR and fasting insulin are satisfactory surrogate
measures.
CONCLUSIONS
In conclusion, we have found metabolic abnormalities, in
particular, alterations in lipid metabolism, in women with PCOS
which persist after correction for central body adiposity. Altera-
tions in HDL lipid proﬁle, Apo A1 and albumin levels were most
signiﬁcant in those women within the stratum of highest waist
circumference whereas those without central obesity were very
similar to the reference population. Our results support the view
that PCOS, hyperandrogenism and abdominal obesity act
independently but also, crucially, in combination, to affect lipid
metabolism (Figure 5). The importance of our results are further
strengthened by a report from Women’s Health Study from the
USA that emphasizes the role of serum HDL-C levels in the risk of
cardiovascular events.57 Our ﬁndings have therefore important
implications for management of long-term health in women with
PCOS. Abdominal obesity itself carries an increased risk of
metabolic dysfunction and its associated pathology; increasing
waist cicumference in women with PCOS hightens those risks.
PCOS has only small effect on the metabolic proﬁle in lean women
but the importance of dietary advice and healthy eating is
particularly clear in women with both PCOS and abdominal
obesity.
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